Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
A Phase 2a clinical trial on up to n=200 male and female subjects 18 years and over who were
diagnosed with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). Subjects
are randomised in approximately a 1:1 ratio to receive standard of care treatment plus either
pyronaridine (PND) or placebo. Quality of life parameters are measured. Visits include
physical examinations, and blood draws for complete blood count with differential (CBC) and
complete metabolic panel (CMP). Survival of subjects is tracked in Year 2.